Is sodium polystyrene sulfonate use associated with a higher risk of serious adverse gastrointestinal events at 30 days?

BEEM Bottom Line

Why is this study important?

Sodium polystyrene sulfonate (SPS) is a commonly prescribed treatment for hyperkalemia. Its harm profile is being increasingly scrutinized as newer albeit very expensive agents (e.g., patiromer and sodium zirconium cyclosilicate) are receiving Federal Drug Administration (FDA) approval in the United States.

Which, if any, threats to validity are most likely to have an impact on the results and how?

Thank you for your interest in the BEEM Journal!

To read the rest of this article or to access the entire collection of BEEM Critical Appraisals, please purchase a subscription at the link below.

If you would like a pre-view, click here to view some sample articles

Premium Content Available Through Subscription

BEEM is a knowledge translation project which aims to extract the most recent, EM relevant, and valid evidence from the volumes of available medical research and deliver it to EM practitioners in an easily consumable format to help guide their clinical practice. This valuable distilled information provided by BEEM is available through BEEM's accredited CME courses or through our online journal.

A BEEM Journal Subscription will provide you with unlimited access to our entire collection of Critical Appraisals for 1 year.